This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
by Zacks Equity Research
Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.
Guardant Health (GH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Guardant Health (GH) closed the most recent trading day at $80.04, moving -1.82% from the previous trading session.
Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Guardant Health (GH) closed at $80.59, marking a +0.93% move from the previous day.
Jazz Enrolls First Patient in Phase II/III Leukemia Study
by Zacks Equity Research
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
by Zacks Equity Research
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China
by Zacks Equity Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
U.S. Consumer Spending Bolsters Economic Growth: 5 Picks
by Zacks Equity Research
U.S. Consumer spending rises in November and with consumer sentiments' higher in December, these five stocks are a good buy.
Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.
ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study
by Zacks Equity Research
ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.
BioCryst Submits NDA for Hereditary Angioedema Candidate
by Zacks Equity Research
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
by Zacks Equity Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
Guardant Health, Gap, GameStop, Microsoft and Sony highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Guardant Health, Gap, GameStop, Microsoft and Sony highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider just delivered 181% revenue growth and 18,500 tests to patients and labs
Top Ranked Momentum Stocks to Buy for December 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 6th
Spero Posts Preliminary Data on SPR720 for Pulmonary Disease
by Zacks Equity Research
Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Kirkland Lake Gold, Target and Guardant Health
by Zacks Equity Research
Zacks.com featured highlights include: Kirkland Lake Gold, Target and Guardant Health
Top Ranked Momentum Stocks to Buy for December 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 2nd
Top 3 Momentum Anomaly Stocks to Buy for Healthy Profits
by Zacks Equity Research
These stocks are currently witnessing short-term pullback in a bull market. So, this could just be the perfect entry point for investors who are looking to enhance their portfolio returns.
Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline
by Zacks Equity Research
Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.
Guardant Health Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Guardant Health.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for November 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 12th